Ontology highlight
ABSTRACT: Background
The impact of sacubitril-valsartan on heart failure (HF) patients with preserved ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety of sacubitril-valsartan in patients with HFpEF.Methods
PubMed and Web of Science were searched without any restrictions from inception to 8 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed.Results
Four trials, with a total of 7008 patients were included. Compared with valsartan, sacubitril-valsartan significantly reduced the rate of HF decompensation and of the combined end point of HF decompensation and all-cause mortality. All-cause mortality, New York Heart Association class improvement and rate of hyperkalemia were not significantly different between the two groups. Regarding safety, sacubitril-valsartan was more likely to increase the risk of hypotension.Conclusion
This meta-analysis suggests that sacubitril-valsartan may be an effective strategy to reduce HF decompensation events in patients with HFpEF.Systematic Review registration: CRD42022336077.
SUBMITTER: Basile C
PROVIDER: S-EPMC9794138 | biostudies-literature | 2023 Jan
REPOSITORIES: biostudies-literature
Basile Christian C Paolillo Stefania S Gargiulo Paola P Marzano Federica F Asile Gaetano G Parlati Antonio Luca Maria ALM Chirico Alfonsina A Nardi Ermanno E Buonocore Davide D Colella Angela A Perrone-Filardi Pasquale P
Journal of cardiovascular medicine (Hagerstown, Md.) 20221115 1
<h4>Background</h4>The impact of sacubitril-valsartan on heart failure (HF) patients with preserved ejection fractions (HFpEF) is uncertain. The purpose of this meta-analysis was to explore the clinical advantages and safety of sacubitril-valsartan in patients with HFpEF.<h4>Methods</h4>PubMed and Web of Science were searched without any restrictions from inception to 8 May 2022 to identify valuable articles. The studies that met the inclusion criteria were analyzed.<h4>Results</h4>Four trials, ...[more]